Ocugen Expands Gene Therapy Trial to Canada
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received approval from Health Canada to begin the Phase 3 liMeliGhT clinical trial for their OCU400 gene therapy. This trial aims to …
Ocugen Expands Gene Therapy Trial to Canada Read More